Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

[1]  J. Englund,et al.  Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults , 2020, Open forum infectious diseases.

[2]  P. Silveira,et al.  Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia? , 2020, Journal of clinical medicine.

[3]  M. Litzow,et al.  Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia , 2020, Therapeutic advances in hematology.

[4]  J. Krueger,et al.  Chimeric antigen receptor T cell therapy comes to clinical practice. , 2019, Current oncology.

[5]  M. Kersten,et al.  Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) , 2019, Haematologica.

[6]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  K. Davis,et al.  Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia , 2018, Blood.

[8]  Michel Sadelain,et al.  Chimeric Antigen Receptor Therapy. , 2018, The New England journal of medicine.

[9]  R. Das,et al.  Abstract 1631: T cell dysfunction in pediatric cancer patients at diagnosis and after chemotherapy can limit chimeric antigen receptor potential , 2018, Clinical Research (Excluding Clinical Trials).

[10]  M. Sadelain,et al.  CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade , 2018, Nature Medicine.

[11]  C. Doglioni,et al.  Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells , 2018, Nature Medicine.

[12]  M. Milone,et al.  Clinical use of lentiviral vectors , 2018, Leukemia.

[13]  M. Sadelain,et al.  Posttransplant chimeric antigen receptor therapy. , 2018, Blood.

[14]  Ping-Pin Zheng,et al.  CAR T cell therapies : ice bucket challenges on glaring safety risks and long-term impacts , 2018 .

[15]  S. Seo,et al.  Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[17]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[18]  K. Cornetta,et al.  Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  D. Maloney,et al.  Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. , 2017, Blood.

[20]  P. Hwu,et al.  Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.

[21]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[22]  M. Wurfel,et al.  Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. , 2017, Cancer discovery.

[23]  E. Mejstrikova,et al.  CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment , 2017, Blood Cancer Journal.

[24]  S. Rosenberg,et al.  Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  S. Riddell,et al.  Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. , 2017, Blood.

[26]  S. Nikiforow,et al.  The Why, what, and How of the New FACT standards for immune effector cells , 2017, Journal of Immunotherapy for Cancer.

[27]  A. Rosenwald,et al.  Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL , 2017, Leukemia.

[28]  A. Wiestner,et al.  Lymphocyte Activation Gene 3-a Novel Therapeutic Target in Chronic Lymphocytic Leukemia , 2016 .

[29]  S. Rosenberg,et al.  Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation , 2016 .

[30]  S. Rosenberg,et al.  Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Katy Rezvani,et al.  Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. , 2016, The Journal of clinical investigation.

[32]  G. Wertheim,et al.  Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. , 2016, Blood.

[33]  M. Liedtke,et al.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.

[34]  J. Englund,et al.  How I vaccinate blood and marrow transplant recipients. , 2016, Blood.

[35]  Daniel Li,et al.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.

[36]  K. Curran,et al.  Toxicity and management in CAR T-cell therapy , 2016, Molecular therapy oncolytics.

[37]  D. Teachey,et al.  Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019) , 2015 .

[38]  Yan Zhang,et al.  Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia , 2015, Oncoimmunology.

[39]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[40]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[41]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[42]  A. Bousvaros,et al.  2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  C. Cruz,et al.  Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. , 2013, Blood.

[44]  Michel Sadelain,et al.  CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia , 2013, PloS one.

[45]  F. Bushman,et al.  Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells , 2012, Science Translational Medicine.

[46]  D. Persons,et al.  Solving the problem of γ-retroviral vectors containing long terminal repeats. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  S. Agarwal,et al.  Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. , 2010, Arthritis and rheumatism.

[48]  Rajesh Chopra,et al.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.